PMID- 22612537
OWN - NLM
STAT- MEDLINE
DCOM- 20121211
LR  - 20131106
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 21
IP  - 7
DP  - 2012 Jul
TI  - Modifying T-cell trafficking to the intestinal as a potential management for 
      inflammatory bowel disease.
PG  - 975-84
LID - 10.1517/13543784.2012.690030 [doi]
AB  - INTRODUCTION: The Inflammatory Bowel Diseases (IBDs) are life-long chronic 
      relapsing incurable inflammatory conditions that usually appear in the first few 
      decades of life. There have been marked advances in the management of these 
      conditions, but none of the currently available therapies are a panacea as they 
      are neither universally efficacious nor will their efficacy necessarily last. 
      There is a desperate need for new therapies that target the immunological 
      deficits within the immune system with low side effects and long-term efficacy. 
      AREAS COVERED: Leukocyte trafficking into the intestinal mucosa is central to the 
      inflammatory pathogenesis in both Crohn's disease (CD) and ulcerative colitis 
      (UC) and modification of this trafficking has the ability to reduce the level of 
      inflammation. The alpha4beta7 integrin heterodimer is highly expressed on the 
      CD4(+)CD45RA-memory T-cell subpopulation located within the intestine, and these 
      play a critical part in the pathogenesis of IBD. EXPERT OPINION: By modifying the 
      integrin and chemokine interactions with their specific receptors, inhibition of 
      alpha4(+) and alpha4beta7(+) T-cell trafficking to the sites of intestinal inflammation is 
      possible with promising outcomes in the management of IBD.
FAU - Lawrance, Ian Craig
AU  - Lawrance IC
AD  - University of Western Australia, Fremantle Hospital, Centre for inflammatory 
      Bowel Diseases, WA and School of Medicine and Pharmacology, T Block, Alma Street, 
      Fremantle, 6059 WA, Australia. Ian.Lawrance@uwa.edu.au
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120522
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Integrins)
RN  - 0 (integrin alpha4beta7)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/administration & dosage/pharmacology/therapeutic use
MH  - CD4-Positive T-Lymphocytes/*drug effects/immunology
MH  - Cell Movement/*drug effects/immunology
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Immunity, Mucosal/drug effects
MH  - Inflammatory Bowel Diseases/*drug therapy/etiology/immunology
MH  - Integrins/*antagonists & inhibitors/biosynthesis
MH  - Intestinal Mucosa/*drug effects/immunology
MH  - T-Lymphocyte Subsets/*drug effects/immunology
MH  - Treatment Outcome
EDAT- 2012/05/23 06:00
MHDA- 2012/12/12 06:00
CRDT- 2012/05/23 06:00
PHST- 2012/05/23 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2012/12/12 06:00 [medline]
AID - 10.1517/13543784.2012.690030 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2012 Jul;21(7):975-84. doi: 
      10.1517/13543784.2012.690030. Epub 2012 May 22.